Gilead Sciences has announced that it has increased its stake in Arcus Biosciences to 33% and expanded its presence on the company’s board of directors to three, deepening its collaboration in cancer drug development. The company made an equity investment of $320 million. After the close, Arcus shares rose 11.8% to $17.2.